EndeavorOTC helps improve attention and focus in adults with ADHD. Credit: Business Wire / Akili.

Digital medicine company Akili has introduced a new immersive mobile video game treatment called EndeavorOTC to enhance attention in adults suffering from attention deficit hyperactivity disorder (ADHD).

EndeavorOTC is developed using the same technology as the company’s EndeavorRx, a prescription digital therapeutic indicated for children aged between eight and 12 years with ADHD, which is also claimed to be the first video game treatment approved by the US Food and Drug Administration (FDA).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

EndeavorOTC can now be obtained nationwide by adults aged 18 years and above, without the need for a prescription and its introduction took place following clinical trial data that was released last month.

The trial results showed that EndeavorOTC demonstrated significant improvements in attention, focus, ADHD symptoms and overall quality of life among adults with ADHD.

Akili CEO Eddie Martucci said: “The core technology inside EndeavorOTC has helped thousands of children with ADHD and recently has shown it dramatically helped adults in our clinical trial improve their focus, time management and organisational skills and their ability to keep track of important items.”

Akili launched EndeavorOTC within the framework of the FDA’s enforcement policy, which was put in place during the Covid-19 pandemic.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This policy aims to streamline the availability of specific low-risk digital health devices that address mental health concerns, ensuring swift access for individuals.

The company utilises its patented Selective Stimulus Management Engine (SSME) core technology to power its digital treatments.

SSME has been validated in more than 12 clinical trials conducted on a range of cognition-affecting conditions, such as depression, multiple sclerosis, autism spectrum disorder and ADHD.